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EPLY
n our study (1) we observed a reduced incidence of atrial
brillation (AF) following coronary artery bypass surgery in pa-
ients receiving polyunsaturated fatty acids (PUFAs). The way
hese compounds could have determined this result is, at present,
nly speculative. Indeed, PUFAs have been demonstrated to have
direct anti-arrhythmic effect in different laboratory models, but
he importance of a concurrent (or prevalent) anti-inflammatory
ction cannot be excluded. In fact, PUFAs have anti-inflammatory
roperties (2), and inflammation, as correctly pointed out by Dr.
orantzopoulos and colleagues can play a fundamental role in
ostcardiac surgery AF. Actually, the efficacy of an anti-inflammatory
herapy in this setting is still not clear owing to conflicting reports.
hereas a single postinduction steroid administration was shown
o prevent postoperative AF (3), a similar protocol was found
neffective in other hands (4). The debate on this subject is thus
till open, but unfortunately a further contribution cannot be
btained by our study, because C-reactive protein (CRP) levels or
ther inflammatory indexes were not routinely collected in our
atients.
Concerning off-pump surgery that could carry a lower risk of
F due to a lesser oxidative and inflammatory response, aside from
eports supporting this assumption (5) there are other studies that
o not confirm this finding (6). In our study the incidence of AF
as similar in patients receiving off-pump surgery (26.3% of 19
ases) and those submitted to on-pump surgery (24.1% of 141
ases). However, our population is too scarce to draw any conclu-
ion on this subject.
Statins have been reported to prevent AF both after cardiac
urgery (7) and after electrical cardioversion (8), possibly by their
leiotropic anti-inflammatory action. In our examination we did
ot observe any difference in AF incidence between patients on
tatins (24.2% of 91 patients) and those not on statins (24.6% of 61
atients). This could be due to the fact that the mean dose of
tatins in our patients was low (15.3 9.2 mg/day simvastatin and
3.2  7.5 mg/day atorvastatin) and the anti-inflammatory and
hus, possibly, anti-arrhythmic effect of statins seems to be related
o the dose. In fact, a recent study reported a significant decrease
f CPR (36.4%) with atorvastatin 80 mg but not with pravastatin
0 mg (5.2%) (9).
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erum Erythropoietin Levels and Infarct Size
ith great interest we read the recent study by Namiuchi et al. (1)
howing an association between high serum erythropoietin levels
nd smaller infarct size in patients with acute myocardial infarction
MI) undergoing primary angioplasty.
Although originally considered a hematopoietic hormone,
rythropoietin (EPO) has been shown to act as a pleiotropic
urvival and growth factor (2). There is accumulating evidence for
protective role of EPO in the heart. We and others have
emonstrated that exogenous EPO administration in rodent
schemia-reperfusion models leads to reduced infarct size and
nhibition of apoptosis (3,4).
Namiuchi et al. (1) suggested that endogenous EPO might also be
rotective against ischemia-reperfusion injury in humans. However,
levated EPO levels could also be a direct reflection of the disease
everity. Serum EPO is elevated in chronic heart failure (CHF)
atients, and this increase is related to the progression of the disease
5). Our group has shown that, in these patients, elevated plasma
PO levels are associated with an impaired prognosis, independent of
emoglobin levels and other established markers of CHF severity (6).
f note, in the study by Namiuchi et al. (1), MI patients with higher
PO levels were found to have significantly higher serum levels of
-type natriuretic peptide (BNP), a sign of hemodynamic impair-
